doi:10.3969/j.issn.1673-8640.2018.04.0010

Abstract

CLC Number:

R446.1

Figures/Tables 2

References 21

[1]	GANEM D,PRINCE A M.Hepatitis B virus infection-natural history and clinical consequences[J]. N Engl J Med,2004,350(11):1118-1129.
[2]	World Health Organization. Hepatitis B [EB/OL]. (2016-04-01)[2017-02-01]. .
[3]	LU F M,ZHUANG H.Management of hepatitis B in China[J]. Chin Med J(Engl),2009,122(1):3-4.
[4]	CHEN C J,YANG H I,SU J,et al.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA,2006,295(1):65-73.
[5]	ILOEJE U H,YANG H I,SU J,et al.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load[J]. Gastroenterology,2006,130(3):678-686.
[6]	赖娅芳,杨岩,盛慧萍. 慢性乙型肝炎患者血清中IFN-γ、IL-10、TGF-β1水平与 HBV-DNA 载量的关系[J]. 宁夏医科大学学报,2010,32(2):211-213.
[7]	牛继华,曹辉,侯彦强. 乙型肝炎病毒DNA载量与血小板参数相关性分析[J]. 国际检验医学杂志,2016,37(2):280.
[8]	李双杰,覃小梅,范宸颖,等. 慢性乙型肝炎患儿HBV DNA载量与肝脏病理、肝功能、肝纤维化血清学指标的相关性分析[J]. 临床肝胆病杂志,2016,32(3):472-475.
[9]	WAI C T,GREENSON J K,FONTANA R J,et al.A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J]. Hepatology,2003,38(2):518-526.
[10]	FORNS X,AMPURDANÈS S,LLOVET J M,et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model[J]. Hepatology,2002,36(4 Pt 1):986-992.
[11]	IMBERT-BISMUT F,RATZIV V,PIERONI L,et al.Biochemical markers of liver fibrosis in patients with hepatitis C virus infection:a prospective study[J]. Lancet,2001,357(9262):1069-1075.
[12]	KODA M,MATUNAGA Y,KAWAKAMI M,et al.FibroIndex:a practical index for predicting significant fibrosis in patients with chronic hepatitis C[J]. Hepatology,2007,45(2):297-306.
[13]	LEE C M,LEUNG T K,WANG H J,et al.Evaluation of the effect of partial splentic embolization on platelet values for liver cirrhosis patients with thrombocytopenia[J]. World J Gastroenterol,2007,13(4):619-622.
[14]	LAFFI G,MARRA F,GRESELE P,et al.Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation[J]. Gastroenterology,1992,103(2):641-646.
[15]	欧宏杰,潘业,刘家俊,等. 慢性乙型肝炎患者外周血小板参数与肝脏组织病理的相关性分析[J]. 肝脏,2016,21(11):915-919.
[16]	都泓莲,彭颖,李烨,等. 慢性乙型肝炎患者血清肝纤维化指标与APRI指数及PLT的相关研究[J]. 检验医学与临床,2017,14(3):357-360.
[17]	高改云,李海中,樊宏伟,等. 乙肝患者血小板指标及生长激素-胰岛素样生长因子轴的变化观察[J]. 中华医院感染学杂志,2016,26(23):5348-5350.
[18]	FELD J J,WONG D K,HEATHCOTE E J.Endpoints of therapy in chronic hepatitis B[J]. Hepatology,2009,49(5 Suppl):S96-S102.
[19]	冼永超,徐茹,杨景毅,等. 慢性乙型肝炎患者血清HBV-DNA 载量与肝组织病理的关系[J]. 中国临床医学,2007,14(3):337-338.
[20]	LIN Z H,XIN Y N,DONG Q J,et al.Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis:an updated meta-analysis[J]. Hepatology,2011,53(3):726-736.
[21]	GÜZELBULUT F,SEZIKLI M,AKKAN-CETINKAYA Z,et al. AST-platelet ratio index in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis B[J]. Turk J Gastroenterol,2012,23(4):353-358.

组别	例数	PLT（×10⁹/L）	MPV（fL）	PDW（%）
CHB组	55	152.98±54.94^**	11.98±1.22^**	15.05±2.84^**
低载量组	20	156.10±65.06^**	11.73±0.95^**	14.84±2.53^*
中载量组	30	152.50±54.26^**	12.02±1.30^**	15.04±3.08^*
高载量组	15	149.40±43.30^**	12.27±1.43^**	15.36±3.07^*
正常对照组	50	228.70±56.09	10.49±1.48	13.13±3.13

组别	例数	PLT（×10⁹/L）	MPV（fL）	PDW（%）
CHB组	55	152.98±54.94^**	11.98±1.22^**	15.05±2.84^**
低载量组	20	156.10±65.06^**	11.73±0.95^**	14.84±2.53^*
中载量组	30	152.50±54.26^**	12.02±1.30^**	15.04±3.08^*
高载量组	15	149.40±43.30^**	12.27±1.43^**	15.36±3.07^*
正常对照组	50	228.70±56.09	10.49±1.48	13.13±3.13

组别	例数	AST（U/L）	APRI
CHB组	55	79.00（46.00~234.00）^*	0.71（0.32~1.58）^*
低载量组	20	50.50（30.25~121.00）^*	0.50（0.22~1.00）^*
中载量组	20	101.50（54.75~233.50）^*	0.99（0.39~1.65）^*
高载量组	15	83.00（59.00~427.00）^*	0.82（0.32~1.83）^*
正常对照组	50	22.00（18.75~75.00）	0.09（0.08~0.13）

组别	例数	AST（U/L）	APRI
CHB组	55	79.00（46.00~234.00）^*	0.71（0.32~1.58）^*
低载量组	20	50.50（30.25~121.00）^*	0.50（0.22~1.00）^*
中载量组	20	101.50（54.75~233.50）^*	0.99（0.39~1.65）^*
高载量组	15	83.00（59.00~427.00）^*	0.82（0.32~1.83）^*
正常对照组	50	22.00（18.75~75.00）	0.09（0.08~0.13）

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 21

Related Articles 15

Recommended Articles

Metrics

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.